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ARTICLE INFO abstract
Background: Bladder sparing therapies are an alternative for Radical Cystectomy 
(RC) for patients with Muscle Invasive Bladder Cancer (MIBC). Addition of chemotherapy 
to External Beam Radiotherapy (EBRT) results in increased toxicity. In properly selected 
patients, re-evaluating the place of EBRT alone might be of interest. 
Methods: A phase 1 trial was initiated for highly selected MIBC patients. Only patients 
with histological diagnosis of MIBC and stage <T3bN0M0 were eligible. After complete 
resection of the Gross Tumor Volume (GTV) and negative node status on Pelvic Lymph 
Node Dissection (PLND), EBRT upto 40 Gy in 20 fractions was administered to the whole 
bladder with a simultaneous integrated boost (SIB) to the GTV according to 3 dose levels: 
a) Level 1: 57.6 Gy (20 x 2.88 Gy, 5 fractions/week, 4 weeks); BED: 61 Gy. 
b) Level 2: 60 Gy (20 x 3.00 Gy, 5 fractions/week, 4 weeks); BED: 64 Gy
c) Level 3: 62.4 Gy (20 x 3.12Gy, 5 fractions/week, 4 weeks); BED: 67 Gy. 
For all levels: BED was calculated with /=13.
A 3+3 design was adopted. Once 1 dose level was proven to be safe (i.e. no acute RTOG 
>Grade3 urinary toxicity) patients were treated up to a higher dose level. Treatment was 
performed with volumetric arc therapy. A plan of day the approach was applied.
Results: The trial was prematurely closed due to poor recruitment after inclusion 
of only 3 patients. One patient received a RC due to pN1 status after PLND. The other 2 
patients were treated up to 57.6 Gy to the GTV. Cystoscopic evaluation revealed no signs of 
recurrence after 39 and 25 months. No grade 4 toxicity was reported. Rectal toxicity was 
limited to grade 1 toxicity. Acute grade 3 urinary toxicity was observed in both patients. 
At latest follow up, urinary toxicity was limited to grade 2 nocturia and grade 2 retention. 
Conclusion: No major toxicity was observed and oncological outcome is excellent 
with more then 2 years of follow up after EBRT alone for MIBC. These preliminary results 
might be considered as hypothesis generating for developing studies with high dose EBRT 
in well-selected MIBC patients.
Introduction
The gold standard for patients with Muscle Invasive Bladder 
Cancer (MIBC) is a Radical Cystectomy (RC) and extended Pelvic 
Lymph Node Dissection (ePLND). Peri-operative mortality rate is ± 
2% and major toxicity is reported in up to 30% of the patients [1]. 
To increase quality of life, bladder-sparing trimodality therapies 
 
(BST) (i.e Transurethral Resection of the Bladder (TURb) + EBRT 
+ chemotherapy) are considered a valuable alternative for RC 
for MIBC patients with similar local control and cause specific 
survival rates as reported in modern surgical series [2,3]. But also, 
with BST grade ≥3 toxicity has been reported in up to 36% of the 
patients [4]. Omitting chemotherapy reduces the risk of developing 
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severe gastro-intestinal, urinary and haematological toxicity at 
the cost of worse disease-free survival [4]. In properly selected 
patients, re-evaluating the place of radiotherapy alone might be 
of interest. Therefore we initiated a phase 1 trial in which EBRT 
with a hypofractionated Simultaneous Integrated Boost (SIB) to 
the original tumor localisation was administered after complete 
resection of the lesion in node negative MIBC patients (Figure 1).
Note: Within the protocol matrix metalloproteinase’s-7 (MMPs) was determined in the blood and urine as a biomarker.
Figure 1: Flow chart of the treatment protocol. 
Material and Methods
We designed a phase 1 trial to evaluate the place of EBRT 
only in highly selected MIBC patients. The ethic committee of 
Ghent University Hospital approved the study on 10/03/2015. 
The study was registered on Clinicaltrials.gov (NCT02748200). 
Eligible patients were patients with histological proven diagnosis 
of MIBC, initial stage <T3b tumours, no distant metastasis, WHO 
performance state 0-2, age ≥ 18 and <80 years, signed informed 
consent and no contra-indication for diffusion-weighted magnetic 
resonance imaging (DW-MRI). Before being referred for EBRT, 
patients underwent a second Transurethral Resection of the 
Bladder (TURb) in order to obtain a complete resection (defined 
as ≤pT1 at re-TURb) as well as an ePLND to exclude pathologically 
involved lymph nodes. At that time gold markers 0,4 x 5 mm (QLRAD, 
Netherlands) were inserted at the edges of the TURb region. 
For each patient 5 different planningsCT’s were performed 
with 5 different bladder volumes following a standardized protocol. 
The clinical target volume consisted of the whole bladder and 
was defined on each planningsCT separately. The whole bladder 
was treated to 40 Gy in 20 fractions, 5 fractions/week, 4 weeks 
in total. Based on the summation of abnormalities seen on pre- 
(initial tumor region) and post TURb (zone of fibrosis) DW-MRI 
images, the tumor region was delineated and defined as a Gross 
Tumor Volume (GTV). The GTV was treated with a simultaneous 
integrated boost (SIB), without extending the 4-weeks treatment 
period. Three different dose levels to the GTV were implemented 
in order to increase the biological equivalent dose (BED), as MIBC 
has been shown to be dose-sensitive [6]. A 3+3 design was adopted. 
Once 1 dose level was proven to be safe (i.e. no acute RTOG >Grade3 
urinary toxicity) patients were treated up to a higher dose level. 
Dose prescription on 50% of the GTV was: 
a) Level 1: 57.6 Gy (20 x 2.88 Gy, 5 fractions/week, 4 weeks); 
BED: 61 Gy. 
b) Level 2: 60 Gy (20 x 3.00 Gy, 5 fractions/week, 4 weeks); BED: 
64 Gy
c) Level 3: 62.4 Gy (20 x 3.12Gy, 5 fractions/week, 4 weeks); BED: 
67 Gy.  For all levels: BED was calculated with α/β=13 (5).
The volume of the rectum and sigmoid receiving 34.3 Gy and 
34.4 Gy were constrained to 64% and 35%, to avoid grade ≥2 rectal 
toxicity with a probability of 90% and 95% respectively [7]. The 
dose received by 2% of the volume, considered as a surrogate for 
the maximum dose, was limited to 40 Gy for the femoral heads, 
small intestine and symphysis. Two sets of 5 treatment plans 
were generated. For one set, 5 treatment plans were optimized 
individually. An accumulated dose distribution was created on 
the third planning CT data set, with a comfortably filled bladder, 
using the deformation fields of deformable image registration. 
The other set of treatment plans were optimized simultaneously 
using Multiple Plan Optimization (MPO). MPO enables the 
specification of dose objectives on individual treatment plans and 
on the accumulated dose distributions. Treatment was delivered 
on an Elekta 18-MV linear accelerator (LINAC, Crawley, UK) with 
Volumetric Arc Therapy (VMAT) technique. 
A daily cone beam CT was performed in order to evaluate 
bladder filling. After matching with the different planning CT’s 
the most appropriate planning was selected. After 10 sessions an 
accumulated dose was calculated based on the delivered plans. 
Considering the dose that was already delivered in daily practice 
during the first 10 sessions, new plans were created. In order to do 
so, the planning procedure was repeated for the last 10 fractions. 
Patients were followed weekly during therapy, 1 month after 
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therapy and 3- monthly thereafter. At each follow up after EBRT a 
standard blood control was performed. In asymptomatic patients 
imaging (cystopscopy of the pelvis and CT thorax/abdomen) 
was performed 3-monthly during the first year and 6-monthly 
thereafter up to a period of 5 years or until progression. A DW-MRI 
was performed at least once after the end of radiotherapy.
The primary outcome is acute RTOG ≥Grade3 toxicity within 
12 weeks after EBRT. Secondary outcome parameters are: local 
control (evaluated on cystoscopy and DW-MRI: if suspicious: 
histopathology), disease free survival (defined as period from start 
of EBRT till local or distant recurrence), cystectomy-free survival 
(defined as period from start of EBRT till salvage cystectomy), 
overall survival (defined as period from start of EBRT till death) 
and assessment of quality of life (EORTC QLQ-C30).
Results
Table 1: Patient characteristics and treatment details.
Characteristics Patient 1 Patient 2 Patient 3
Age at diagnosis (year) 78 65 74
Tumor characteristics
Oncological antecedents
2013: pTa G2 TCC treated with 
TURb  2016: initial diagnosis of 
pT2 G3 TCC
2016: initial diagnosis 
of pT2 G3 TCC2015: recurrent pT2 G3 TCC: 
start of Mitomycine 4 cycles
Stage at time of inclusion in the trial pT2cN0M0 G3 TCC pT2cN0M0 G3 TCC pT2cN0M0 G3 TCC
Localisation of the tumor right ureteral orifice vesico-ureteral junction right ostium left
Treatment
Re-TURb + PLND 
+ implantation of 
markers
date 2,5 months after initial diagnosis
1,5 month after initial 
diagnosis 7/9/2016
pathology pT0 pN0 (0/20) cM0 pTa pN0 (0/10) cM0 pT2 pN1 (1/8) cM0
Radiotherapy
date 3 weeks after re-TURb + PLND 4 weeks after re-TURb + PLND Patient was excluded 
from the trial due 
to pN1 status and 
received neo-adjuvant 
chemotherapy 
followed by a radical 
cystectomy
OTT (days) 29 days 30 days
dose
bladder: D50: 40 Gy (20 x 2 Gy) bladder: D50: 40 Gy (20 x 2 Gy)
tumor region: D50: 57.6 Gy (20 
x 2.88 Gy)
tumor region: D50: 57.6 
Gy (20 x 2.88 Gy)
Abbreviations: TURb: transurethral resection of the bladder, PLND: pelvic lymph node dissection
Table 2: Patient’s outcome and toxicity per case.        
Patient 1 Patient 2
Follow up (months) after diagnosis of MIBC 39 25
Oncological status no evidence of disease on last cystoscopic evaluation   
no evidence of disease on last cystoscopic 
evaluation




Grade 1 frequency, incontinence, nocturia
Grade 2 NR hematuria, dysuria, incontinence, urgency
Grade 3
nocturia (hospitalisation for 





Grade 1 frequency rectal blood loss, diarrhea, abdominal pain, flatulence, frequency, mucus loss
Grade 2 NR NR
Grade 3 NR NR
Late toxicity
urinary
Grade 1 retention, dysuria incontinence
Grade 2 nocturia retention




diarrhea, frequency, mucus loss, 
flatulence, abdominal cramps, 
constipation
mucus loss, urgency, frequency
Grade 2 NR NR
Grade 3 NR NR
Abbreviations: TURb: Transurethral Resection of the Bladder, SCLC: Small Cell Lung Carcinoma, T: Tumor Stage, N: Nodal Stage, M: Metastases NR: not 
reported
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The study was closed prematurely due to poor recruitment. 
Three patients were included in the study. One patient was 
excluded due to presence of positive lymph nodes at Pelvic Lymph 
Node Dissection. The patients, tumor and treatment characteristics 
are described in Table 1. Patient’s outcome and toxicity per case are 
presented in Table 2. At latest follow up gastro-intestinal toxicity 
was limited to grade 1 constipation for the first patient and no 
gastro-intestinal toxicity for the second patient. Urinary toxicity at 
latest follow up was grade 2 nocturia and grade 1 retention for the 
first patient and grade 2 retention and grade 1 incontinence for the 
second patient. 
Discussion
Proper patient selection is of utmost importance to improve 
the outcome of MIBC treated with BST. According to international 
guidelines, ideal candidates for trimodality treatment (including 
a TURb followed by radiochemotherapy) are patients with 
pT2cN0 MIBC who received a visible complete Transurethral 
Resection of the Bladder (TURb) and have no signs of carcinoma 
in situ or hydronephrosis [8-10]. In even more selected patients, 
chemotherapy might be omitted in order to reduce the risk of 
developing toxicity. Therefore, we initiated a phase 1 trial to explore 
the place of EBRT only with a SIB to the GTV in highly selected MIBC 
patients. For the latter several conditions needed to be fulfilled 
before patients were eligible for inclusion. First, we aimed to have 
a visibly complete and pathologically complete, defined as ≤pT1 
disease, TURb by performing a re-TURb at time of insertion of the 
gold markers and PLND. The impact of a visibly complete resection 
on survival has been well recognized [11].
Additionally, we requested an ePLND as the sensitivity of 
current imaging in detecting involved lymph nodes is limited. By 
performing an ePLND, patients with occult lymph node metastasis 
were excluded from our trial. Moreover, retrospective surgical series 
have indicated that absence of pelvic lymph node involvement on 
ePLND (pN0), is a prognostic factor for cancer specific survival 
[12]. Additionally, an ePLND eradicates microscopic disease, which 
results in improved outcome both in pN+ and pN0 disease [13]. A 
dose response relationship has been suggested for bladder cancer. 
For every additional 1 Gy a gain in 5 years OS has been suggested of 
7.5% [14]. In analogy to other tumour sites one can presume that 
tumour recurrence is most often observed in the initial tumour 
region [15]. Increasing the dose to that region might result in better 
clinical outcome without compromising toxicity [16]. In order 
to define this region in case of MIBC modern imaging techniques 
can be used. Despite promising results regarding the role of DW-
MRI in local and locoregional staging of MBIC, DW-MRI is not 
routinely performed nowadays. For local staging DW-MRI has a 
sensitivity and specificity of 92.3%-96% and 97.6-98.1% [17,18]. 
After transurethral resection, DW-MRI can differentiate between 
tumor recurrence and postoperative inflammation or fibrosis. The 
standard radiotherapy regimen for MIBC is irradiation of the whole 
bladder with a 2- to 3-cm margin to a dose of 60–66 Gy at 1.8 to 2 Gy 
fractions. However, the optimal schedule still has to be determined. 
Nowadays results after hypofractionated schedules are neither 
better nor worse than regimens of 60 Gy in 30 fractions [19]. 
Randomized trials comparing radiotherapy with a radiosen-
sitizer versus radiotherapy alone have indicated a significant ad-
vantage for the combined regimen in terms of disease-free survival 
[4,20]. However, patient’s selection in our trial was far stricter. For 
example, only patients with a unique lesion were eligible. Also, the 
largest advantage of combined radiotherapy and a radio sensitiz-
er has been observed in patients with more advanced stages that 
were excluded from our trial. Some trials have studied the place of 
TURb alone in MIBC. Although some long-term control has been de-
scribed, the risk of having a relapse is substantial [21]. Therefore, 
we decided to perform a SIB to the initial tumor region as well as 
not to omit prophylactic irradiation of the whole bladder up to 40 
Gy, which is probably enough to eradicate microscopic disease. It 
has also been demonstrated that a cystoscopic evaluation underes-
timates the extend of the disease discouraging an approach of not 
treating the full bladder [22]. 
The presented approach can also be an alternative for 
brachytherapy, which applies similar inclusion criteria [23]. With 
brachytherapy 5-year OS rates have been published that are 
comparable to the ones reported in surgical series [24]. Despite 
good clinical outcome and acceptable toxicity brachytherapy is not 
widely adopted due to lack of brachytherapy experience and logistic 
implications. The rapid dose fall-off as well as the accurate coverage 
of the tumor region with brachytherapy are major advantages in 
favour of brachytherapy compared to EBRT. With a plan-of the day- 
approach the inaccuracy of patient positioning in case of bladder 
irradiation can be prevented. Studies describing adaptive planning, 
including a plan of the day approach, reported increased coverage 
of the bladder and tumor with reduction of the doses delivered to 
the surrounding organs at risk [25]. 
Also, the implementation of modern radiation techniques such 
as intensity-modulated arc therapy allows escalating the dose to 
the initial tumor region while sparing intestinal loops and rectal 
mucosa [26-27]. Unfortunately, our study was closed prematurely 
due to poor accrual. Conclusions on maximum tolerated dose 
can therefore not be drawn from our study. Nevertheless, the few 
patients that were included in our trial did not develop major 
toxicity and oncological outcome is excellent with more than 2 
years of follow up. Therefore, our study might be considered as 
hypothesis generating for developing studies with high dose EBRT 
in well-selected MIBC patients.
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